Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer

The lack of response to treatment in most lung cancer patients suggests the value of broadening the benefit of anti-PD-1/PD-L1 monotherapy. Judicious dosing of antiangiogenic agents such as apatinib (VEGFR2-TKI) can modulate the tumor immunosuppressive microenvironment, which contributes to resistan...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer immunology research 2019-04, Vol.7 (4), p.630-643
Hauptverfasser:	Zhao, Sha, Ren, Shengxiang, Jiang, Tao, Zhu, Bo, Li, Xuefei, Zhao, Chao, Jia, Yijun, Shi, Jinpeng, Zhang, Limin, Liu, Xiaozhen, Qiao, Meng, Chen, Xiaoxia, Su, Chunxia, Yu, Hui, Zhou, Caicun, Zhang, Jun, Camidge, D Ross, Hirsch, Fred R
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Monoclonal, Humanized - pharmacology Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use B7-H1 Antigen - antagonists & inhibitors B7-H1 Antigen - metabolism Carcinoma, Lewis Lung - blood supply Carcinoma, Lewis Lung - drug therapy Carcinoma, Lewis Lung - immunology Carcinoma, Lewis Lung - metabolism Cell Line, Tumor Humans Lung Neoplasms - blood supply Lung Neoplasms - drug therapy Lung Neoplasms - immunology Lung Neoplasms - metabolism Lymphocytes, Tumor-Infiltrating - drug effects Lymphocytes, Tumor-Infiltrating - immunology Male Mice, Inbred C57BL Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed Cell Death 1 Receptor - metabolism Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Pyridines - pharmacology Pyridines - therapeutic use Tumor Microenvironment - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!